newsfilter
← Latest News
Business Wire·

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

MANE
  • Veradermics, Inc. (NYSE: MANE) will host an investor call & live webcast on Monday, November 9, 2026, at 8:00 am ET to review top-line results from Part B of its Phase 3 registration-directed trial (Study '302').
  • The trial evaluated VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss.
  • VDPHL01 utilizes a gel matrix for sustained absorption to avoid high peak concentrations while extending time above the hair growth threshold.
  • If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male & female patients.
  • The drug is protected by a broad patent library with the earliest expiring patent term in 2043.
  • Pattern hair loss affects approximately 80 million people in the U.S., with no new FDA-approved prescription medicines approved in nearly 30 years.
  • The global pattern hair loss market is projected to reach approximately $30 billion by 2028.